Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib

  • Santosh Vilaschand Gandhi AISSMS College of Pharmacy, Pune-411001
  • Barkha Govindlal Kapoor AISSMS College of Pharmacy, Pune-411001

Abstract

A simple, sensitive and reproducible spectrophotometric method for the analysis of Baricitinib in pure form and in its dosage form has been developed. Baricitinib is a synthetic antineoplastic and immunomodulating  drug. Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. Developed method obeyed beer’s law in a concentration range of 10-60 µg/ml with a correlation coefficient (R2) of 0.993. Quantification was carried out at 250 nm. Percentage assay of Baricitinib was found to be close to 100 %. The results of analysis have been validated statistically and recovery studies confirmed the accuracy of the proposed method.

Downloads

Download data is not yet available.
Statistics
589 Views | 417 Downloads
How to Cite
1.
Gandhi S, Kapoor B. Development and Validation of UV Spectroscopic Method for Estimation of Baricitinib. JDDT [Internet]. 15Aug.2019 [cited 19Jan.2022];9(4-s):488-91. Available from: http://www.jddtonline.info/index.php/jddt/article/view/3230